A 71-patient study reported a 12-week lung-function signal: mean forced vital capacity rose 98.4 ml in the highest-dose group and fell 20.3 ml with placebo.
1
This provides controlled human evidence for Insilico’s drug-development case, but the small, short study does not establish pivotal efficacy.
Recursion reports an early patient signal for REC-4881
In its second-quarter results release, Schrödinger reported $32.5 million of software revenue at a 71% gross margin, alongside $23 million of drug-discovery revenue that included a $10 million milestone.
Insilico announces first dosing in rentosertib phase III
'/%3e%3cpath%20id='Vector'%20d='M20.7611%2018.7207C20.7611%2018.7207%2017.3365%2036.1152%2028.2392%2043.9638L10.7517%2043.9777C10.621%2031.3823%2015.0227%2027.7579%2020.7611%2018.7207Z'%20fill='%23242121'/%3e%3c/g%3e%3cdefs%3e%3clinearGradient%20id='roadstar-logo-gradient'%20x1='22'%20y1='0'%20x2='22'%20y2='44'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%23242121'/%3e%3cstop%20offset='1'%20stop-color='%23242121'%20stop-opacity='0.4'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e){kind=small}
⌘ K
By Intermission· 2,621 words
Which companies benefit the most from AI Drug Discovery?
Rentosertib’s randomized phase IIa results are published
[3]A 71-patient study reported a 12-week lung-function signal: mean forced vital capacity rose 98.4 ml in the highest-dose group and fell 20.3 ml with placebo.
This provides controlled human evidence for Insilico’s drug-development case, but the small, short study does not establish pivotal efficacy.
Recursion reports an early patient signal for REC-4881
[21]Recursion reported a median 43% reduction in polyp burden among 12 efficacy-evaluable patients in its open-label TUPELO study.
Schrödinger announces TuneLab access through LiveDesign
[6]Schrödinger said its LiveDesign platform would be a priority interface for participating biotech companies to access Lilly’s TuneLab workflows.
Lilly and NVIDIA announce an AI drug-discovery lab
[12]The companies announced up to $1 billion of joint investment in talent, infrastructure and compute over five years.
Roche announces its NVIDIA AI factory
[10]Roche described 2,176 on-premises GPUs and combined on-premises and cloud infrastructure exceeding 3,500 Blackwell GPUs.
Schrödinger reports its software and discovery revenue mix
[5]In its second-quarter results release, Schrödinger reported $32.5 million of software revenue at a 71% gross margin, alongside $23 million of drug-discovery revenue that included a $10 million milestone.
Insilico announces first dosing in rentosertib phase III
[4]Insilico announced first patient dosing in its Chinese GENESIS-IPF-3 study. The planned trial has 320 participants and 52 weeks of treatment.
Sources
Comments